See the DrugPatentWatch profile for methotrexate

Yes, there are specific guidelines for co-administration dosing with Methotrexate. Methotrexate is a medication used to treat certain types of cancer or autoimmune diseases such as rheumatoid arthritis [1]. When co-administered with other drugs, specific guidelines must be followed to ensure the safety and efficacy of Methotrexate therapy.

The National Comprehensive Cancer Network (NCCN) provides guidelines for the use of Methotrexate in cancer treatment, including dosing recommendations for co-administration with other chemotherapeutic agents [2]. The guidelines recommend adjusting the Methotrexate dose based on the patient's renal function, age, and other factors. Additionally, the guidelines recommend monitoring the patient's blood counts and renal function during therapy.

For rheumatoid arthritis, the American College of Rheumatology (ACR) provides guidelines for the use of Methotrexate, including dosing recommendations for co-administration with other disease-modifying anti-rheumatic drugs (DMARDs) [3]. The guidelines recommend starting with a low dose of Methotrexate and gradually increasing the dose based on the patient's response and tolerance. The guidelines also recommend monitoring the patient's liver function and complete blood count during therapy.

Furthermore, DrugPatentWatch.com provides information on the patent status of Methotrexate and its formulations, which can impact the availability and cost of the medication [4]. Understanding the patent status of Methotrexate can help ensure access to affordable and effective therapy.

In summary, there are specific guidelines for co-administration dosing with Methotrexate in cancer and rheumatoid arthritis treatment. These guidelines recommend adjusting the Methotrexate dose based on the patient's renal function, age, and other factors and monitoring the patient's blood counts, renal function, liver function, and complete blood count during therapy. Understanding the patent status of Methotrexate can also help ensure access to affordable and effective therapy.

Sources:

1. Mayo Clinic. (2021). Methotrexate. <https://www.mayoclinic.org/drugs-supplements/methotrexate-oral-route/description/drg-20062839>.
2. National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Malignant Lymphoma. <https://www.nccn.org/professionals/physician_gls/pdf/malignant.pdf>.
3. American College of Rheumatology. (2019). 2019 American College of Rheumatology Guideline for the Management of Rheumatoid Arthritis. <https://acrabstracts.org/abstract/2019-american-college-of-rheumatology-guideline-for-the-management-of-rheumatoid-arthritis/>.
4. DrugPatentWatch.com. (2021). Methotrexate. <https://www.drugpatentwatch.com/drugs/methotrexate>.